Zoetis Inc (ZTS) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $1.70, surpassing Wall Street's consensus estimate of $1.64 by $0.06. Revenue matched expectations at $2.4 billion, indicating steady performance amid a competitive landscape.
The company, headquartered in Parsippany, New Jersey, specializes in the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for animals. With a diverse product portfolio serving both companion animals and livestock, Zoetis operates across two segments: the United States and International. The firm markets its products in approximately 45 countries worldwide.
Management will host an earnings conference call to discuss these results and share insights on business performance. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.
As of November 7, 2025, Zoetis holds a market cap of $52.69 billion and a P/E ratio of 20.17. The company is set to report its next earnings on August 2, 2026, with EPS estimates of $1.8747 and revenue expectations of $2.6 billion.